{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:20:26Z","timestamp":1788405626787,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40264-026-01665-7","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:37:05Z","timestamp":1774867025000},"page":"883-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements"],"prefix":"10.1007","volume":"49","author":[{"given":"Dawn","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Toseef","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Aurelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bobbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dhanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Gravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hauben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Yeomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-8378","authenticated-orcid":false,"given":"Miranda","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1665_CR1","unstructured":"EMA. Definition of an ADR 2026. https:\/\/www.ema.europa.eu\/en\/glossary-terms\/adverse-drug-reaction. Accessed 10 Mar 2026."},{"key":"1665_CR2","doi-asserted-by":"publisher","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). CIOMS Cumulative glossary with a focus on pharmacovigilance (Version 2.4). Geneva: CIOMS; 2026. Available from:   https:\/\/doi.org\/10.56759\/ocef1297. https:\/\/cioms.ch\/publications\/product\/cioms-cumulative-pharmacovigilance-glossary\/. Accessed 23 Mar 2026.","DOI":"10.56759\/ocef1297"},{"issue":"Suppl. 1","key":"1665_CR3","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2105\/AJPH.2004.059204","volume":"95","author":"KJ Rothman","year":"2005","unstructured":"Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(Suppl. 1):S144\u201350. https:\/\/doi.org\/10.2105\/AJPH.2004.059204.","journal-title":"Am J Public Health"},{"issue":"7","key":"1665_CR4","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/bph.17458","volume":"182","author":"S Topouzis","year":"2025","unstructured":"Topouzis S, Papapetropoulos A, Alexander SPH, Cortese-Krott M, Kendall DA, Martemyanov K, et al. Novel drugs approved by the EMA, the FDA and the MHRA in 2024: a year in review. Br J Pharmacol. 2025;182(7):1416\u201345. https:\/\/doi.org\/10.1111\/bph.17458.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1665_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","volume":"79","author":"RJ Andrade","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023;79(3):853\u201366. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.033.","journal-title":"J Hepatol"},{"key":"1665_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1193413","volume":"3","author":"TA Hammad","year":"2023","unstructured":"Hammad TA, Afsar S, McAvoy LB, Le Louet H. Aspects to consider in causality assessment of safety signals: broadening the thought process. Front Drug Saf Regul. 2023;3:1193413. https:\/\/doi.org\/10.3389\/fdsfr.2023.1193413.","journal-title":"Front Drug Saf Regul"},{"issue":"1","key":"1665_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21\u201337. https:\/\/doi.org\/10.2165\/00002018-200831010-00003.","journal-title":"Drug Saf"},{"issue":"11","key":"1665_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40264-018-0690-y","volume":"41","author":"S Comfort","year":"2018","unstructured":"Comfort S, Dorrell D, Meireis S, Fine J. MOdified NARanjo Causality Scale for ICSRs (MONARCSi): a decision support tool for safety scientists. Drug Saf. 2018;41(11):1073\u201385. https:\/\/doi.org\/10.1007\/s40264-018-0690-y.","journal-title":"Drug Saf"},{"issue":"4","key":"1665_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/pds.4637","volume":"28","author":"I Oosterhuis","year":"2019","unstructured":"Oosterhuis I, Zweers P, R\u00fcmke H, Muller-Hansma A, van Puijenbroek EP. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines. Pharmacoepidemiol Drug Saf. 2019;28(4):544\u201350. https:\/\/doi.org\/10.1002\/pds.4637.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1665_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jclinepi.2005.08.012","volume":"59","author":"Y Arimone","year":"2006","unstructured":"Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Molimard M, Moore N, et al. A new method for assessing drug causation provided agreement with experts\u2019 judgment. J Clin Epidemiol. 2006;59(3):308\u201314. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.08.012.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1665_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jsps.2015.01.010","volume":"24","author":"LM Khan","year":"2016","unstructured":"Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 2016;24(4):485\u201393. https:\/\/doi.org\/10.1016\/j.jsps.2015.01.010.","journal-title":"Saudi Pharm J"},{"key":"1665_CR12","unstructured":"WHO. World Health Organization-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. 2013. https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment. Accessed 10 Mar 2026."},{"issue":"3-4","key":"1665_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/009286158401800312","volume":"18","author":"BE Wiholm","year":"1984","unstructured":"Wiholm BE. The Swedish drug-event assessment methods. special workshop-regulatory. Drug Inf J. 1984;18(3\u20134):267\u20139. https:\/\/doi.org\/10.1177\/009286158401800312.","journal-title":"Drug Inf J"},{"issue":"5","key":"1665_CR14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59975","volume":"16","author":"PK Manjhi","year":"2024","unstructured":"Manjhi PK, Singh MP, Kumar M. Causality, severity, preventability and predictability assessments scales for adverse drug reactions: a review. Cureus. 2024;16(5):e59975. https:\/\/doi.org\/10.7759\/cureus.59975.","journal-title":"Cureus"},{"issue":"2","key":"1665_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1665_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/009286159302700222","volume":"27","author":"P-H Hsu","year":"1993","unstructured":"Hsu P-H, Stoll RW. Causality assessment of adverse events in clinical trials: II. An algorithm for drug causality assessment. Drug Inf J. 1993;27(2):387\u201394. https:\/\/doi.org\/10.1177\/009286159302700222.","journal-title":"Drug Inf J"},{"key":"1665_CR17","first-page":"318","volume":"7","author":"A Emanueli","year":"1980","unstructured":"Emanueli A, Sacchetti G. An algorithm for the classification of untoward events in large scale clinical trials. Agents Actions Suppl. 1980;7:318\u201322.","journal-title":"Agents Actions Suppl"},{"issue":"3","key":"1665_CR18","first-page":"207","volume":"41","author":"E Loupi","year":"1986","unstructured":"Loupi E, Ponchon AC, Ventre JJ, Evreux JC. Imputability of a teratogenic effect. Therapie. 1986;41(3):207\u201310.","journal-title":"Therapie"},{"issue":"1","key":"1665_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. https:\/\/doi.org\/10.3390\/ijms17010014.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1665_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60\u20138. https:\/\/doi.org\/10.1038\/clpt.2009.252.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1665_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40801-023-00413-y","volume":"11","author":"M Ohta","year":"2024","unstructured":"Ohta M, Miyawaki S, Yokota S, Yoshimoto M, Maruyama T, Koide D, et al. Causality assessment between drugs and fatal cerebral haemorrhage using electronic medical records: comparative evaluation of disease-specific and conventional methods. Drugs Real World Outcomes. 2024;11(2):221\u20139. https:\/\/doi.org\/10.1007\/s40801-023-00413-y.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"1665_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/0091270011433327","volume":"53","author":"W Du","year":"2013","unstructured":"Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol. 2013;53(1):87\u201395. https:\/\/doi.org\/10.1177\/0091270011433327.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1665_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028096","volume":"6","author":"RM Gallagher","year":"2011","unstructured":"Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE. 2011;6(12):e28096. https:\/\/doi.org\/10.1371\/journal.pone.0028096.","journal-title":"PLoS ONE"},{"issue":"6","key":"1665_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/jep.12033","volume":"19","author":"M de Boer","year":"2013","unstructured":"de Boer M, Kiewiet JJ, Boeker EB, Ramrattan MA, Dijkgraaf MG, Lie AHL, et al. A targeted method for standardized assessment of adverse drug events in surgical patients. J Eval Clin Pract. 2013;19(6):1073\u201382. https:\/\/doi.org\/10.1111\/jep.12033.","journal-title":"J Eval Clin Pract"},{"key":"1665_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/2042098621991280","volume":"12","author":"JB Sharma","year":"2021","unstructured":"Sharma JB, Krishnamurthy MN, Awase A, Joshi A, Patil V, Noronha V, et al. Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy. Ther Adv Drug Saf. 2021;12:2042098621991280. https:\/\/doi.org\/10.1177\/2042098621991280.","journal-title":"Ther Adv Drug Saf"},{"issue":"11","key":"1665_CR26","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/jnnp-2021-326924","volume":"92","author":"M Butler","year":"2021","unstructured":"Butler M, Tamborska A, Wood GK, Ellul M, Thomas RH, Galea I, et al. Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. J Neurol Neurosurg Psychiatry. 2021;92(11):1144\u201351. https:\/\/doi.org\/10.1136\/jnnp-2021-326924.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1665_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1517\/14740338.2013.774371","volume":"12","author":"R Teschke","year":"2013","unstructured":"Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf. 2013;12(3):339\u201366. https:\/\/doi.org\/10.1517\/14740338.2013.774371.","journal-title":"Expert Opin Drug Saf"},{"key":"1665_CR28","unstructured":"WHO. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed. 2019 update. 2019. https:\/\/www.who.int\/publications\/i\/item\/9789241516990. Accessed 10 Mar 2026."},{"issue":"4","key":"1665_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674\u201380. https:\/\/doi.org\/10.1345\/aph.1H423.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"1665_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.rmedc.2009.01.004","volume":"2","author":"MJ Doherty","year":"2009","unstructured":"Doherty MJ. Algorithms for assessing the probability of an adverse drug reaction. Respir Med CME. 2009;2(2):63\u20137. https:\/\/doi.org\/10.1016\/j.rmedc.2009.01.004.","journal-title":"Respir Med CME"},{"issue":"3-4","key":"1665_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/009286158401800313","volume":"18","author":"ML Mashford","year":"1984","unstructured":"Mashford ML. The Australian method of drug-event assessment. Special workshop-regulatory. Drug Inf J. 1984;18(3\u20134):271\u20133. https:\/\/doi.org\/10.1177\/009286158401800313.","journal-title":"Drug Inf J"},{"issue":"3","key":"1665_CR32","first-page":"265","volume":"2","author":"DA Lane","year":"1987","unstructured":"Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C. The causality assessment of adverse drug reactions using a Bayesian approach. Pharm Med. 1987;2(3):265\u201383.","journal-title":"Pharm Med"},{"key":"1665_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/009286159202600419","author":"CA Naranjo","year":"1992","unstructured":"Naranjo CA, Lanct\u00f4t KL. A Consultant\u2019s View on the Role of Bayesian Differential Diagnosis in the Safety Assessment of Pharmaceuticals. Drug Information Journal. 1992;26(4):593-601. https:\/\/doi.org\/10.1177\/009286159202600419.","journal-title":"Drug Inf J"},{"issue":"2","key":"1665_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/j.1552-4604.1994.tb03978.x","volume":"34","author":"KL Lanctot","year":"1994","unstructured":"Lanctot KL, Naranjo CA. Computer-assisted evaluation of adverse events using a Bayesian approach. J Clin Pharmacol. 1994;34(2):142\u20137. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb03978.x.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1665_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00210-025-04412-4","volume":"399","author":"F Lau","year":"2026","unstructured":"Lau F, Seifert R. Comparison of drug approvals of the FDA and EMA between 2013 and 2023. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):279\u201399. https:\/\/doi.org\/10.1007\/s00210-025-04412-4.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"1665_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clinthera.2023.12.008","volume":"46","author":"D Cooper","year":"2024","unstructured":"Cooper D, Platt RW, van Hunsel F, Davies M, Yeomans A, Lane S, et al. The International Working Group on New Developments in Pharmacovigilance: advancing methods and communication in pharmacovigilance. Clin Ther. 2024;46(7):565\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.008.","journal-title":"Clin Ther"},{"issue":"2","key":"1665_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.32725\/jab.2023.010","volume":"21","author":"P Pradhan","year":"2023","unstructured":"Pradhan P, Lavallee M, Akinola S, Escobar Gimenes FR, Berard A, Methot J, et al. Causality assessment of adverse drug reaction: a narrative review to find the most exhaustive and easy-to-use tool in post-authorization settings. J Appl Biomed. 2023;21(2):59\u201366. https:\/\/doi.org\/10.32725\/jab.2023.010.","journal-title":"J Appl Biomed"},{"issue":"4","key":"1665_CR38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.11124\/JBIES-21-00483","volume":"20","author":"Z Munn","year":"2022","unstructured":"Munn Z, Pollock D, Khalil H, Alexander L, McLnerney P, Godfrey CM, et al. What are scoping reviews? Providing a formal definition of scoping reviews as a type of evidence synthesis. JBI Evidence Synthesis. 2022;20(4):950\u20132. https:\/\/doi.org\/10.11124\/JBIES-21-00483.","journal-title":"JBI Evidence Synthesis"},{"key":"1665_CR39","unstructured":"REDCap. Research electronic data capture. 2025. https:\/\/project-redcap.org\/. Accessed 10 Mar 2026."},{"issue":"7","key":"1665_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1665_CR41","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.14309\/ajg.0000000000001836","volume":"117","author":"PH Hayashi","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ. RECAM: A new and improved, computerized causality assessment tool for DILI diagnosis. Am J Gastroenterol. 2022;117(9):1387\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000001836.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1665_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijmedinf.2007.08.010","volume":"77","author":"Y Koh","year":"2008","unstructured":"Koh Y, Yap CW, Li SC. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int J Med Inform. 2008;77(6):421\u201330. https:\/\/doi.org\/10.1016\/j.ijmedinf.2007.08.010.","journal-title":"Int J Med Inform"},{"issue":"2","key":"1665_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2515\/therapie\/2013016","volume":"68","author":"Y Arimone","year":"2013","unstructured":"Arimone Y, Bidault I, Dutertre JP, Gerardin M, Guy C, Haramburu F, et al. Updating the French method for the causality assessment of adverse drug reactions. Therapie. 2013;68(2):69\u201376. https:\/\/doi.org\/10.2515\/therapie\/2013016.","journal-title":"Therapie"},{"issue":"6","key":"1665_CR44","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/pds.3531","volume":"23","author":"TC Cheetham","year":"2014","unstructured":"Cheetham TC, Lee J, Hunt CM, Niu F, Reisinger S, Murray R, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf. 2014;23(6):601\u20138. https:\/\/doi.org\/10.1002\/pds.3531.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1665_CR45","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40264-017-0541-2","volume":"40","author":"E Scalfaro","year":"2017","unstructured":"Scalfaro E, Streefkerk HJ, Merz M, Meier C, Lewis D. Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced Llver injury: the PV-RUCAM. Drug Saf. 2017;40(8):715\u201327. https:\/\/doi.org\/10.1007\/s40264-017-0541-2.","journal-title":"Drug Saf"},{"issue":"3","key":"1665_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/03007995.2017.1383891","volume":"34","author":"L Zorzela","year":"2018","unstructured":"Zorzela L, Mior S, Boon H, Gross A, Yager J, Carter R, et al. Tool to assess causality of direct and indirect adverse events associated with therapeutic interventions. Curr Med Res Opin. 2018;34(3):407\u201314. https:\/\/doi.org\/10.1080\/03007995.2017.1383891.","journal-title":"Curr Med Res Opin"},{"key":"1665_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.artmed.2018.07.005","volume":"91","author":"PP Rodrigues","year":"2018","unstructured":"Rodrigues PP, Ferreira-Santos D, Silva A, Polonia J, Ribeiro-Vaz I. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network. Artif Intell Med. 2018;91:12\u201322. https:\/\/doi.org\/10.1016\/j.artmed.2018.07.005.","journal-title":"Artif Intell Med"},{"issue":"7","key":"1665_CR48","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/pds.4841","volume":"28","author":"B O'Donovan","year":"2019","unstructured":"O\u2019Donovan B, Rodgers RM, Cox AR, Krska J. Development and preliminary validation of an instrument to enable laypersons to assess suspected side effects from medicines. Pharmacoepidemiol Drug Saf. 2019;28(7):1023\u201331. https:\/\/doi.org\/10.1002\/pds.4841.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1665_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/hep.32327","volume":"76","author":"PH Hayashi","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76(1):18\u201331. https:\/\/doi.org\/10.1002\/hep.32327.","journal-title":"Hepatology"},{"issue":"5","key":"1665_CR50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/bjd.15423","volume":"177","author":"NR Adler","year":"2017","unstructured":"Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol. 2017;177(5):1234\u201347. https:\/\/doi.org\/10.1111\/bjd.15423.","journal-title":"Br J Dermatol"},{"key":"1665_CR51","doi-asserted-by":"publisher","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). CIOMS Severe Cutaneous Adverse Reactions (SCAR). 2025.  Geneva: CIOMS; 2025. Available from:   https:\/\/doi.org\/10.56759\/lrty1600. https:\/\/cioms.ch\/publications\/product\/scar-report\/.  Accessed 23 Mar 2026.","DOI":"10.56759\/lrty1600"},{"key":"1665_CR52","doi-asserted-by":"publisher","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). CIOMS Drug-induced liver injury (DILI). 2020. Geneva: CIOMS; 2020. Available from:   https:\/\/doi.org\/10.56759\/ojsg8296. https:\/\/cioms.ch\/publications\/product\/drug-induced-liver-injury\/.  Accessed 23 Mar 2026.","DOI":"10.56759\/ojsg8296"},{"issue":"11","key":"1665_CR53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331\u20136. https:\/\/doi.org\/10.1016\/0895-4356(93)90102-7.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1665_CR54","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-a","volume":"11","author":"C B\u00e9nichou","year":"1990","unstructured":"B\u00e9nichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272\u20136. https:\/\/doi.org\/10.1016\/0168-8278(90)90124-a.","journal-title":"J Hepatol"},{"issue":"3","key":"1665_CR55","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.hepres.2004.08.005","volume":"30","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan: comparison with two previous scales. Hepatol Res. 2004;30(3):148\u201354. https:\/\/doi.org\/10.1016\/j.hepres.2004.08.005.","journal-title":"Hepatol Res"},{"key":"1665_CR56","unstructured":"Observational Health Data Sciences and Informatics. 2025. https:\/\/www.ohdsi.org\/. Accessed 10 Mar 2026."},{"issue":"44","key":"1665_CR57","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","volume":"31","author":"AE Tozzi","year":"2013","unstructured":"Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013;31(44):5041\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.087.","journal-title":"Vaccine"},{"issue":"12","key":"1665_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018587","volume":"7","author":"JD Zeitoun","year":"2017","unstructured":"Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, et al. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. BMJ Open. 2017;7(12):e018587. https:\/\/doi.org\/10.1136\/bmjopen-2017-018587.","journal-title":"BMJ Open"},{"key":"1665_CR59","unstructured":"EMA. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10\u201313 June 2024. 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024. Accessed 10 Mar 2026."},{"issue":"23","key":"1665_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237291","volume":"13","author":"P Bellavite","year":"2024","unstructured":"Bellavite P, Donzelli A, Isidoro C. The WHO algorithm for causality assessment of adverse effects following immunization with genetic-based anti-COVID-19 vaccines: pitfalls and suggestions for improvement. J Clin Med. 2024;13(23):7291. https:\/\/doi.org\/10.3390\/jcm13237291.","journal-title":"J Clin Med"},{"key":"1665_CR61","unstructured":"U.S. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Updated 2021. The pink book: course textbook. https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/index.html. Accessed 10 Mar 2026."},{"issue":"6","key":"1665_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2(6):100170. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100170.","journal-title":"JHEP Rep"},{"issue":"24","key":"1665_CR63","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","volume":"28","author":"CK Tan","year":"2022","unstructured":"Tan CK, Ho D, Wang LM, Kumar R. Drug-induced autoimmune hepatitis: a minireview. World J Gastroenterol. 2022;28(24):2654\u201366. https:\/\/doi.org\/10.3748\/wjg.v28.i24.2654.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1665_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-022-01052-z","volume":"23","author":"BC Yang","year":"2023","unstructured":"Yang BC, Castells MC. Utilizing biologics in drug desensitization. Curr Allergy Asthma Rep. 2023;23(1):1\u201311. https:\/\/doi.org\/10.1007\/s11882-022-01052-z.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"1665_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40264-022-01157-4","volume":"45","author":"R Ball","year":"2022","unstructured":"Ball R, Dal Pan G. \u201cArtificial intelligence\u201d for pharmacovigilance: ready for prime time? Drug Saf. 2022;45(5):429\u201338. https:\/\/doi.org\/10.1007\/s40264-022-01157-4.","journal-title":"Drug Saf"},{"issue":"5","key":"1665_CR66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40264-022-01163-6","volume":"45","author":"Y Cherkas","year":"2022","unstructured":"Cherkas Y, Ide J, van Stekelenborg J. Leveraging machine learning to facilitate individual case causality assessment of adverse drug reactions. Drug Saf. 2022;45(5):571\u201382. https:\/\/doi.org\/10.1007\/s40264-022-01163-6.","journal-title":"Drug Saf"},{"issue":"7","key":"1665_CR67","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40264-025-01531-y","volume":"48","author":"A Abate","year":"2025","unstructured":"Abate A, Poncato E, Barbieri MA, Powell G, Rossi A, Peker S, et al. Off-the-shelf large language models for causality assessment of individual case safety reports: a proof-of-concept with COVID-19 vaccines. Drug Saf. 2025;48(7):805\u201320. https:\/\/doi.org\/10.1007\/s40264-025-01531-y.","journal-title":"Drug Saf"},{"key":"1665_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jbi.2016.06.006","volume":"62","author":"W Wang","year":"2016","unstructured":"Wang W, Kreimeyer K, Woo EJ, Ball R, Foster M, Pandey A, et al. A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports. J Biomed Inform. 2016;62:78\u201389. https:\/\/doi.org\/10.1016\/j.jbi.2016.06.006.","journal-title":"J Biomed Inform"},{"issue":"7","key":"1665_CR69","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.clinthera.2024.03.006","volume":"46","author":"M Hauben","year":"2024","unstructured":"Hauben M, Rafi M. Knowledge graphs in pharmacovigilance: a step-by-step guide. Clin Ther. 2024;46(7):538\u201343. https:\/\/doi.org\/10.1016\/j.clinthera.2024.03.006.","journal-title":"Clin Ther"},{"issue":"2","key":"1665_CR70","first-page":"102","volume":"2","author":"X Wu","year":"2024","unstructured":"Wu X, Duan R, Ni J. Unveiling security, privacy, and ethical concerns of ChatGPT. J Inform Intell. 2024;2(2):102\u201315.","journal-title":"J Inform Intell"},{"issue":"3","key":"1665_CR71","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/picr.picr_290_23","volume":"15","author":"MK Desai","year":"2024","unstructured":"Desai MK. Artificial intelligence in pharmacovigilance: opportunities and challenges. Perspect Clin Res. 2024;15(3):116\u201321. https:\/\/doi.org\/10.4103\/picr.picr_290_23.","journal-title":"Perspect Clin Res"},{"issue":"3","key":"1665_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16083","volume":"45","author":"M Garc\u00eda-Cort\u00e9s","year":"2025","unstructured":"Garc\u00eda-Cort\u00e9s M, Matilla-Cabello G, Lucena MI. Methods for causality assessment of idiosyncratic drug-induced liver injury. Liver Int. 2025;45(3):e16083. https:\/\/doi.org\/10.1111\/liv.16083.","journal-title":"Liver Int"},{"issue":"13","key":"1665_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131588","volume":"15","author":"R Teschke","year":"2025","unstructured":"Teschke R, Eickhoff A, Danan G. Drug-induced autoimmune hepatitis: robust causality assessment using two different validated and scoring diagnostic algorithms. Diagnostics Basel. 2025;15(13):1588. https:\/\/doi.org\/10.3390\/diagnostics15131588.","journal-title":"Diagnostics Basel"},{"issue":"1","key":"1665_CR74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376. https:\/\/doi.org\/10.1002\/hep.22322.","journal-title":"Hepatology"},{"issue":"10","key":"1665_CR75","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/apt.18271","volume":"60","author":"A Fettiplace","year":"2024","unstructured":"Fettiplace A, Marcinak J, Merz M, Zhang HT, Kikuchi L, Regev A, et al. Review article: recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients. Aliment Pharmacol Ther. 2024;60(10):1293\u2013307. https:\/\/doi.org\/10.1111\/apt.18271.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1665_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092622","volume":"13","author":"S Stewart","year":"2024","unstructured":"Stewart S, G\u00f3mez L\u00f3pez de las Huertas A, Jim\u00e9nez-Gonz\u00e1lez M, Carcas AJ, Borobia AM, Ram\u00edrez E. ALDRESS: a retrospective pilot study to develop a pharmacological causality algorithm for drug reaction with eosinophilia and systemic symptoms (DRESS). J Clin Med. 2024;13(9):2622. https:\/\/doi.org\/10.3390\/jcm13092622.","journal-title":"J Clin Med"},{"issue":"8","key":"1665_CR77","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/15563650.2025.2515239","volume":"63","author":"S Sinno-Tellier","year":"2025","unstructured":"Sinno-Tellier S, Delepine D, Vodovar D, Braganca C, Sponga M, Puskarczyk E, et al. Evaluation of the reproducibility and validity of the use of the causality assessment method for poisonings designed and applied by the French poison control centres. Clin Toxicol (Phila). 2025;63(8):570\u20138. https:\/\/doi.org\/10.1080\/15563650.2025.2515239.","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01665-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:02:12Z","timestamp":1783702932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1665"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01665-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"While the IWG was funded by pharmaceutical companies, the authors declare that the research was conducted in the absence of any commercial or financial influence. The views expressed in this paper are those of the authors and do not necessarily reflect those of the authors\u2019 institutions or their stakeholders. Eug\u00e8ne van Puijenbroek is an Editorial Board member of\n                      Drug Safety\n                      . The author was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. The scoping review was solely based on published data available in the public domain.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All of the authors contributed to the conception and design of the work. Several authors were involved in eligibility assessment (DC, RP, MD), data extraction (DC, MA, TA, AB, SD, CG, DM, KM, EP, AY MD) and\/or adjudication (DC, TA, AB, DM, KM, AY). All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}